Work

Facio-scapulo-humeral dystrophy: clinical follow-up and role of chromosome X inactivation in female patients - SHP2: a novel therapeutic target in MuSK-myasthenia

Year: 2018
Type: dissertation
Study design: Observational Study
Abstract: Part I. Facio-scapulo-humeral dystrophy: clinical follow-up and role of chromosome X inactivation in female patients. Facio-scapulo-humeral dystrophy (FSHD) is an autosomal dominant muscular dystrophy characterized by high prevalence and clinical variability. It involves facial muscles, shoulder girdle and, in most severe cases, the lower limbs. Over 95% of patients have a contraction of D4Z4 repeated units on chromosome 4q35 that causes hypomethylation of the region and the overexpression of a toxic factor, DUX4. In about 5% of patients, called FSHD2, D4Z4 hypomethylation is due to mutations of SMCHD1, a gene involved in the inactivation of chromosome X during embryotic development. The aim of this study was to evaluate the clinical progression of FSHD over a 5-year follow-up using the Clinical Severity Score (CSS), a scale previously validated by the Italian Network for FSHD. Furthermore, considering the role of SMCHD1 in the epigenetic control of the chromosome X and the differences in severity between genders, the inactivation pattern of the chromosome X was analysed in order to test whether it could represent a genetic modifier of the disease. The sample consisted of 55 FSHD patients (29 males and 26 females) from the Neuromuscular Centre of Padova. All subjects carried a pathological D4Z4 fragment between 17-40 Kb. Patients who had been evaluated with CSS at T0 were re-evaluated after an average period of 5 years (T1). The score of each muscle region, the total CSS and the MRC score were recorded and compared between T0 and T1. Chromosome X inactivation was analysed in 38 FSHD1 and 4 FSHD2 females measuring the degree of methylation of the CAG repeated sequence of the androgen receptor gene. Genomic DNA was digested with methylation-sensitive restriction enzymes (HpAII and HhAI), amplified by PCR and finally genotyped. 48 healthy individuals were studied as controls and X inactivation patterns were correlated to muscle impairment measured by CSS. After 6 years of follow-up, the mean CSS difference between T0 and T1, and MRC score at biceps, triceps and tibialis anterior reached significance only in the probands group. There was no difference at shorter follow-up times or between relatives. Disease progression appeared independent of the size of D4Z4 fragment and no differences were found between genders. X-inactivation pattern was normally distributed in patients and controls. There was a moderate linear correlation between the percentage of X-inactivation and the severity of the shoulder girdle involvement, but not with any other muscle groups. In conclusion, FSHD symptoms progress slowly over time and, although CSS represents a valuable tool for patient assessment, it lacks sensitivity for the detection of subtle clinical modifications even over a five-year period. Therefore, its use in follow-up appears to be limited. Moreover, the X inactivation pattern in FSHD patients mirrors the normal distribution observed in healthy females and correlates only modestly with the severity of the disease. These latter findings suggest that different genetic regulators are involved in the full phenotypic expression of the disease, and make evaluation of potential therapies difficult. Part II. SHP2: a novel therapeutic target in MuSK-myasthenia. Muscle Specific Kinase antibody myasthenia gravis (MuSK-MG) is an autoimmune disease that impairs neuromuscular transmission leading to widespread muscle weakness and fatigability. Under physiological conditions, agrin activates the LRP4-MuSK complex, initiating a phosphorylation cascade that culminates with the clustering of acetylcholine receptors (AChRs). SH2 domain-containing phosphatase (SHP2) is a negative regulator of AChR clustering that inhibits MuSK phosphorylation. In MuSK-MG, (auto)antibodies against MuSK, mainly of the IgG4 subclass, block MuSK interaction with LRP4 and, therefore, its activation. The smaller population of MuSK IgG1-3 appear to act by a different mechanism. Although MuSK-MG is a treatable disease, a therapy that targets specifically its pathogenic mechanisms is still not available. The aim of this study was to confirm and extend preliminary findings that demonstrated the in vitro effects of a specific SHP2 inhibitor, NSC-87877, as a potential specific treatment for MuSK-MG. Total IgG and IgG subclasses (IgG1-3, IgG4) were purified from plasma of 3 MuSK-MG patients. MuSK-Ab titres were measured by radioimmunoassay. To test the effects of NSC-87877 on MuSK phosphorylation and AChR clustering, C2C12 myotubes were used. The myotubes were incubated with increasing concentrations of NSC-87877 at different time intervals (from 15 to 360 minutes) using agrin and DMEM as positive and negative controls respectively. To test whether the drug was able to reverse the pathogenic effects of MuSK-Abs, myotubes were then exposed to agrin either with MuSK total IgG, IgG1-3 or IgG4, in the presence or absence of NSC-87877. MuSK expression and tyrosine phosphorylation were detected by western blotting, and the phosphorylation expressed as the ratio of the densitometry values of phospho-tyrosine MuSK to total MuSK. For AChR cluster quantification, myotubes were labelled with α-bungataroxin-594 followed by image acquisition and analysis with ImageJ software. For all experiments 20 images were scanned, coded, and the number of clusters > 5 μm counted using ImageJ. In the absence of agrin, NSC-87877 caused a dose-dependent increase in both MuSK phosphorylation and AChR clustering, reaching a maximum at 100 μM, after 40 minutes of incubation. 100 μM NSC-87877 enhanced MuSK phosphorylation in the presence of MuSK total IgG and purified IgG4 while no significant change was observed with purified IgG1-3. Nevertheless, MuSK total IgG and both subclass fractions caused the dispersal of AChR clusters (see also Koneczny et al, 2013), and NSC-87877 was able to reverse their pathological effects in all samples. SHP2 inhibition by NSC-87877 induced MuSK phosphorylation and increased AChR clustering regardless of direct stimulation by agrin. Moreover, NSC-87877 effectively induced MuSK activation despite the inhibitory effects of MuSK IgG4 antibodies, and enhanced AChR clustering in the presence of all the different IgG subclasses. Therefore, irrespectively of the MuSK IgG subclass, SHP2 inhibition represents a potential therapeutic strategy in MuSK myasthenia and further studies should access its efficacy and reliability in vivo.
Language: English
Open Access status: green
OpenAlex ID: W2912602341
Cites: 247
Cited by:
Related to: 10